In a prospective study, researchers sought to determine the noninferiority of palonosetron to ondansetron in pediatric patients with cancer receiving moderate or high emetogenic chemotherapy.
FDA issues black box warning for rolapitant regarding the potential for anaphylaxis, anaphylactic shock, and other hypersensitivity reactions in patients receiving the injectable emulsion for CINV prophylaxis.
Data presented at ASH 2017 illustrates the effectiveness of 2 prophylactic antiemetic regimens in pediatric patients receiving moderately or highly emetogenic chemotherapy.
A review of 12 antiemetic regimens identified 3 that may be more effective than conventional regimens, a study presented at SABCS 2017 has shown.
A small study of 50 patients undergoing FOLFOX for CRC determined if adding aprepitant to standard antiemetic prophylactic treatment would improve CINV in this patient population.
A post-hoc analysis of 2 clinical trials was conducted to determine the safety and effectiveness of NEPA for managing CINV in patients with lung cancer who received platinum-based chemotherapy.
Fosaprepitant is used to prevent CINV in adult patients, and this phase 2b dose-ranging study of pediatric patients aged newborn to 17 years determined the appropriate doses for younger patients.
A randomized study was conducted to determine the efficacy of prophylactic prochlorperazine in reducing opioid-induced nausea and vomiting in patients with cancer receiving opioids for pain management.
Delayed CINV was improved significantly in patients receiving highly emetogenic chemotherapy for cancer when thalidomide was added to palonosetron and dexamethasone regimen.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|